Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMax-CD4 in Active Rheumatoid Arthritis
NCT00042406Phase 3Terminated
- Sponsor
- Genmab
- Start
- Mar 2002
- Primary completion
- Mar 2003
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of zanolimumab in rheumatoid arthritis (RA), sponsored by Genmab. Started Mar 2002; status: terminated.
02
Drugs
zanolimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00042406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042406.